In a Country Known for Agave, Condesa a Gin Top Honors: Condesa Gin Named Mexico's Spirit of the Year 2025
In a country internationally revered for its tequila and mezcal, a gin has just taken top national honors: Condesa Gin
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / In a country internationally revered for its tequila and mezcal, a gin has just taken top national honors. Condesa Gin Clásica has been named 'Spirit of the Year - Mexico' at the 2025 London Spirits Competition with 97 points, and also won a Gold Medal at the 2025 San Francisco World Spirits Competition-putting Mexico City firmly on the global gin map.Clasica Bottle on the car seat A Condesa Gin Clásica bottle sits on a vintage leather car seat, bathed in soft natural light blending effortless elegance with a sense of adventure.
Condesa Gin Clásica has been named 'Spirit of the Year - Mexico' at the 2025 London Spirits Competition, surpassing a field of iconic agave distillates. The award, which comes with a Gold Medal and an impressive 97-point rating, signals a changing tide in Mexican spirits-and puts Mexico City on the map of global gin, a space long dominated by Europe. The win marks a historic moment for the capital's exploding mixology scene. Not only is Condesa Gin Clásica now the highest-rated spirit from Mexico at the competition, but both of the brand's flagship gins-Condesa Gin Clásica and Prickly Pear & Orange Blossom-also took home Gold Medals at the 2025 San Francisco World Spirits Competition, cementing this mixologist favorite as one of the world's leading gins.
Contact InformationMayra Berenyce Ascencio Sanchez Marketing Director +52 5561153619
SOURCE: MAYRA BERENYCE ASCENCIO SANCHEZ
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
4 hours ago
- Indianapolis Star
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25% As recently announced, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar SAN FRANCISCO, CA / ACCESS Newswire / June 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today provided updates on the company's orphan disease intestinal failure program. Jaguar, through Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics, is currently supporting two independent proof-of-concept investigator-initiated trials (IITs), and conducting two placebo-controlled Phase 2 studies, of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) in the United States, European Union, and/or Middle East/North Africa regions. As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, initial proof-of-concept results from the ongoing exploratory, single-arm open label non-randomized IIT of crofelemer in Abu Dhabi in pediatric intestinal failure patients show that crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in the first participating MVID patient by up to 27% and in the first participating SBS-IF patient by up to 12.5%. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output – an indicator of improved nutrient oral absorption. Data from the third patient enrolled in the IIT is expected. Completion of Napo's randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned. 'Our strategy is to seek business development partnerships for license rights for development and commercialization of Jaguar's intestinal failure products – with the goal of generating non-dilutive funding for Jaguar,' said Lisa Conte, Jaguar's Founder and CEO. 'I attended the BIO International Convention in Boston last week and took part in productive meetings at the event.' 'Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the ongoing IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval,' said Conte. 'We're excited to report that enrollment in the company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for MVID in pediatric patients is at approximately 25% and patient screening is continuing. For the company's placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for SBS-IF in adults, enrollment is above 10%, and patient screening is continuing,' said Conte. 'Additionally, enrollment is continuing in the two ongoing proof-of-concept IITs. These are important milestones in development efforts for crofelemer for the treatment and management of intestinal failure related to these devastating orphan diseases and will continue to generate IIT data.' Based on the initial findings of the ongoing IIT in Abu Dhabi, crofelemer's paradigm-shifting antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in patients with intestinal failure due to MVID and short bowel syndrome. The observed groundbreaking TPN reduction is particularly compelling for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management and for which no approved drug treatments exist, or any potential approach to reduce TPN. The initial proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program that may accelerate regulatory approval pathways in the EU. This data may also support qualification of crofelemer for the FDA's Breakthrough Therapy program for expedited regulatory approval in the US. Additional proof-of-concept results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions. About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as 'dragon's blood,' of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that completion of Napo's Phase 2 study of crofelemer in pediatric MVID patients will occur mid-2026, Jaguar's expectation that the two ongoing proof-of-concept IITs will continue to generate data, Jaguar's expectation that data from the third patient enrolled in the IIT in Abu Dhabi is expected, Jaguar's expectation that its strategy of seeking business development partnerships for license rights for development and commercialization of Jaguar's intestinal failure products may support generation of non-dilutive funding for Jaguar, Jaguar's expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval of crofelemer for MVID, Jaguar's expectation that crofelemer's mechanism of action may have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in pediatric MVID and SBS-IF patients, Jaguar's expectation that proof-of-concept data in MVID may support crofelemer's potential inclusion in the EMA's PRIME program for expediated and assisted regulatory approval and in the FDA's Breakthrough Therapy program for expedited regulatory approval in the US, Jaguar's expectation that additional proof-of-concept results from IITs will be available throughout 2025, and Jaguar's expectation that published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for MVID and SBS-IF. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Indianapolis Star
4 hours ago
- Indianapolis Star
Auto Claim Specialists Wins Fight for Mandatory Right to Appraisal in Texas
Throwing Stones to Take Down a Giant FORT WORTH, TX / ACCESS Newswire They said it couldn't be done. They said it was impossible. No one believed the battle to require the Right to Appraisal be included in all Texas auto policies could be won – no one except Robert McDorman, founder of Auto Claim Specialists, whose devotion to ensuring the safety of roadways in the Lone Star State inspired him to take up a slingshot in this iteration of the classic 'David versus Goliath' showdown. For nearly a decade, McDorman tirelessly led the charge to persuade lawmakers of the importance of mandatory appraisal rights, and his hard work has finally paid off – Senate Bill 458 has been adopted into the Texas Insurance Code and made law! The war against the Appraisal Clause began in 2015 when State Farm removed this vital consumer protection from their Texas policies. McDorman took up the mantle and began sounding the alarm through meetings with the Texas Department of Insurance (TDI) to alert them to the potential dangers that such an action presented to drivers and their roadways. Bills proposing mandatory appraisal rights were presented in the 2021 and 2023 sessions, but both times, the session ended before a conclusive vote; however, the third time was the charm! Senate 458, the 2025 iteration of this legislative initiative, was fast-tracked through the process, obtaining unanimous approval from both the Senate and the House during every review. That's a far cry from eight years ago when 'legislators didn't believe there was a need for mandatory appraisal rights,' McDorman recalls. 'They hadn't heard anything about it and couldn't be convinced that it was a problem that needed their attention.' Legislators' disinterest did not dissuade him from his mission. McDorman continued to beat the drum for mandatory appraisal, meeting with TDI five times and appearing before various legislative committees a total of eight times to educate them on the impact of the Appraisal Clause. 'Every time someone told me 'no,' I pushed forward. I refused to believe it was a waste of time.' His dogged determination ultimately attracted attention, leading TDI to acknowledge the need for legislators to 'establish policy form appraisal guidance' in its 2022 Biennial Report, and in its Report to the 88th Texas Legislature, the Office of Public Insurance Counsel (OPIC) expressed increasing concern with 'restrictions on appraisal in policy forms filed by top insurers [which] can adversely impact consumers, who buy insurance to make sure damage to their property will be repaired or replaced. Without appraisal, they may be forced to choose between accepting the insurer's offer and paying out-of-pocket for any disputed amount or taking on the costly and time-consuming burden of going to court.' OPIC reiterated those concerns in its Report to the 89th Texas Legislature, listing appraisal as its first recommendation, restating its previous position and adding, 'Restrictions on appraisal can remove an important consumer protection that saves the parties and the judicial system time and resources. Appraisal is usually the consumer's only economically realistic option for challenging the amount an insurer offers to repair or replace property. Filing a lawsuit is expensive – often more expensive than the amount of an auto repair claim. Eliminating appraisal leaves the consumer stuck in the middle of a dispute between the insurer and providers over the amount of loss, resembling the balance billing trap that health insurance consumers found themselves in before the Legislature addressed that issue.' They recommended that legislators 'amend the Texas Insurance Code to require personal auto and residential property insurers in Texas to preserve the insurance consumer's right to invoke appraisal in disputes regarding the cost to repair or replace covered property.' While McDorman stood at the forefront of the battlefield on this important issue, he had an entire army marching with him, throwing one stone at a time to combat this egregious violation of consumer rights. The Auto Body Association of Texas (ABAT) stood shoulder to shoulder with McDorman, providing pecuniary support and volunteering time and energy to promote all three iterations of the proposed mandatory appraisal legislation. In addition to significant personal financial contributions, ABAT President Burl Richards joined McDorman in several meetings with TDI and appearances before legislative committees to express the significance of this undertaking. Consumer advocacy watchdog Texas Watch also offered valuable support throughout the process through its efforts to generate public awareness, help educate legislators and the compilation of Impact of Auto Appraisal (available at a report that demonstrated the monetary affect that Right to Appraisal typically has on claim settlements. McDorman humbly credits the passage of Senate Bill 458 to Joe Collins, whose experience with the appraisal process yielded a large settlement from State Farm (see Recognizing how detrimental a similar under-indemnification situation might be for others, especially those who do not have the protections provided through the Appraisal Clause, Collins donated his entire settlement to the fight for mandatory appraisal rights. 'If that money goes toward making sure all Texas policies include the Right to Appraisal, then I'm helping everybody.' (Full story available at Collins entrusted the funds to Auto Claim Specialists and McDorman who used them to establish the Mandatory Appraisal Rights Advocacy Trust. Collins' story inspired many others from across the country to contribute to a GoFundMe fundraiser, creating a national movement. 'Joe's generosity and dedication to 'doing the right thing' resonated with people, and they wanted to support our efforts,' McDorman offers praise and gratitude to everyone who contributed to the fight. 'Many people helped us get to where we are, but Joe's donation was instrumental to building that momentum. I'm gratified by the passage of the bill which demonstrates that I was a worthy steward of his trust.' Countless others aided in achieving this victory for mandatory appraisal rights as well. Other public adjusters, multiple law firms and lobbyists stepped up, donating time, money and energy to support the cause. McDorman's own contributions are unquantifiable. Beyond the financial commitment he made personally and on behalf of Auto Claim Specialists, he spent thousands of hours away from the business, devoted to compiling data to present to legislators to help them understand why their constituents deserve the Right to Appraisal. 'The devil is in the detail,' he explains. 'Every time I shared information, I had the evidence to support it. The insurance industry tends to be a little less transparent with their reporting, which provides the opportunity for dishonesty and undervaluation; I put a microscope on that practice and demonstrated how often policyholders get cheated. Now, all of our legislators understand how this provision protects their constituents, and I commend them for doing what's right for all Texans, to help ensure safe roadways. The fact that the vote was unanimous from the House and the Senate – across both sides of the aisle – proves what a great job we did educating them on how the Appraisal Clause is a vital mechanism to ensure vehicle owners are reimbursed for all the operations required to safely repair their cars.' He equates the legislative victory with the concept of slaying a giant. 'We went up against really big odds; the insurance industry has deep pockets which enables them to walk all over people most of the time. Often, that happens because we are afraid to fight them; we're afraid to lose. But when you're doing the right thing for the right reason, it's worthwhile to keep going, to continue the fight to make a difference. That's what we did, and our efforts paid off – this was the people's fight…and the people fought and WON!' Senate Bill 458, which seeks to ensure that all Texas insurance policies 'must contain an appraisal provision' and specifies that this appraisal provision 'is intended to provide a type of dispute resolution process solely to determine the amount of loss when that amount is in dispute between the policyholder and the insurer,' will go into effect on September 1, 2025. (Read the bill in its entirety at McDorman is ecstatic that all Texas policyholders will soon have access to the vital protection of Right to Appraisal, and he 'looks forward to the next step, working with TDI to establish guidelines and appropriate time triggers.' ### Auto Claim Specialists is a national public insurance adjuster agency dedicated to ensuring consumers receive a fair settlement on their auto claims. Founded in 2017 by consumer advocate Robert McDorman, Auto Claim Specialists seeks to hold insurers accountable for fully indemnifying their policyholders for damages suffered by establishing the true value of losses. More information can be found online at or by calling 817-756-5482. For further information, please contact: claims@ Contact Information Thomas Greco thomas@ 9736676922 SOURCE: Auto Claim Specialists View the original press release on ACCESS Newswire
Miami Herald
5 hours ago
- Miami Herald
Arrive AI Celebrates Nasdaq Debut by Ringing Opening Bell with Early Supporters, Pioneering the Future of Autonomous Delivery
INDIANAPOLIS, INDIANA / ACCESS Newswire / June 23, 2025 / Arrive AI (NASDAQ:ARAI) - a pioneering autonomous delivery network anchored by Arrive Points™ - is set to mark a pivotal moment in its journey by ringing Nasdaq's opening bell on July 3, 2025. More than 300 of the company's foundational investors, alongside team members, will join the celebration, highlighting the incredible support that fueled Arrive AI's ascent to the public market. "This isn't just about ringing a bell; it's a testament to the vision and unwavering belief of our early investors who stood with us every step of the way," said Arrive CEO Dan O'Toole. "This landmark achievement is for everyone who joined our journey and made this moment possible. We are the real 'we the people' story!" Arrive AI officially began publicly trading on May 15, 2025. The company is rapidly transforming the autonomous delivery landscape with its Arrive Points, intelligent, networked smart mailboxes that serve as universal access points for both traditional and autonomous deliveries. This proprietary network offers an ever-growing suite of services, ranging from real-time data tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. The system seamlessly integrates with smart home devices such as doorbells, lighting and security systems, to streamline and secure the entire last-mile delivery experience. O'Toole's journey from designing the prototype Arrive Point on a napkin to ringing the Nasdaq bell began in 2014 when he sought U.S. Patent Office protection for his smart mailbox design. In doing so, he edged out Amazon by four days and other industry leaders by weeks. He secured that foundational patent in 2017 and has continued to refine the product and has also developed an AI-driven network and platform. Arrive AI now holds eight patents for its proprietary technology. Six additional patents are pending. Arrive AI has a total of 58 patents pending for its ALM solution filed across 22 countries and has secured several trademarks. See details at The latest patent highlights the Arrive Points' cutting-edge capabilities, including: Climate control: Ensuring the integrity of sensitive deliveries,Battery charging and exchange station: Supporting the evolving needs of autonomous vehicles,Advanced safety features: A collector for identifying explosive materials and anthrax, and ultraviolet and ozone applicators to eradicate disease, viruses and harmful materials, andComprehensive monitoring: Weather monitoring; vehicle and package tracking; facial recognition camera and software for both humans and pets; local two-way speakers; and integrated flood light and strobe LED lighting. Arrive AI is actively collaborating with leaders in the healthcare industry where efficiency, accuracy and security are paramount for deliveries. O'Toole emphasizes the platform's vast potential for data tracking and other services, solidifying its position as a universal access point for the entire autonomous logistics industry. -30- About Arrive AI: Arrive AI's patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at Media contact: Cheryl Reed at media@ Investor Relations Contact: Alliance Advisors IR at Cautionary Note Regarding Forward Looking Statements This news release and statements of Arrive AI's management in connection with this news release or related events contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would" ,"optimistic" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI's public filings for more complete information, including the risk factors that may affect future results, which are available for review at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law. SOURCE: Arrive AI Inc.
